他汀类药物在肝硬化相关并发症中的防治作用

The Role of Statins in the Prevention and Treatment of Complications Related to Cir-rhosis

他汀类药物作为羟甲基戊二酰辅酶(HMG-CoA)还原酶抑制剂,通过抑制甾醇生物合成途径中的关键步骤、减少胆固醇生物合成,故目前作为降低血脂的重要药物、显著降低心血管事件发生率,而近些年来,关于他汀类药物在慢性肝病、肝硬化及相关并发症等防治领域研究逐渐增多。他汀类药物除调节血脂外,还有抗炎、抗氧化、免疫调节、抗细菌真菌等作用,他汀类药物在防治肝硬化相关并发症方面显露出巨大潜能。本文就目前关于他汀类药物在防治肝硬化并发症方面研究做一综述探讨。

As a hydroxymethylglutaryl coenzyme (HMG-CoA) reductase inhibitor, statins reduce cholesterol biosynthesis by inhibiting key steps in the sterol biosynthesis pathway. Therefore, they are cur-rently used as important drugs to reduce blood lipids and significantly reduce the incidence of car-diovascular events. In recent years, research on statins in the prevention and treatment of chronic liver disease, cirrhosis and related complications has gradually increased. Statins not only regulate blood lipids, but also have anti-inflammatory, anti-oxidation, immune regulation, anti-bacterial and fungal effects. Statins have shown great potential in the prevention and treatment of cirrho-sis-related complications. This article reviews the current research on statins in the prevention and treatment of complications of cirrhosis.